Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peptides

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Peptides. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-023757-11 Sponsor Protocol Number: myDC/pDCinstageIIImelanoma Start Date*: 2014-11-06
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection
    Medical condition: melanoma patients with regional lymph node metastases (stage III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003025-18 Sponsor Protocol Number: VAPER Start Date*: 2015-05-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: In Vivo Generation of Optimal Tumour Antigen-specific Anticancer Immune Responses, by Vaccination with Human Telomerase Reverse Transcriptase (hTERT) Peptides, in Combination with Specific Adjuvant...
    Medical condition: Advanced malignancies
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006369-10 Sponsor Protocol Number: BTT-gpASIT003 Start Date*: 2009-01-22
    Sponsor Name:BioTech Tools S.A.
    Full Title: Preliminary assessment of the clinical tolerability, safety and immunogenicity of three different doses of grass pollen-derived peptides for oral use in antigen-specific immunotherapy of seasonal a...
    Medical condition: seasonal allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002373-35 Sponsor Protocol Number: T153/2016 Start Date*: 2016-07-04
    Sponsor Name:
    Full Title: The Effects of Dietary Peptides on Human Brown Adipose Tissue
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000228-14 Sponsor Protocol Number: LUC 05-003 Start Date*: 2006-02-21
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Immunization of disease-free melanoma patients with different HLA-A2 peptides.
    Medical condition: We want to vaccine HLA-A2 patients who had a cutaneous melanoma at the following AJCC stage T3b-T4 N0 M0, Tx N1-3 M0, Tx Nx M0. Disease-free after surgery. With no previous immunizations with the s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002531-29 Sponsor Protocol Number: NaturalDCformCRPC Start Date*: 2014-10-30
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: A randomized phase IIa study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients
    Medical condition: Asymptomatic or minimally symptomatic, chemo-naive mCRPC patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005322-19 Sponsor Protocol Number: MIND-DC Start Date*: 2016-01-21
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed ...
    Medical condition: melanoma patients with regional lymph node metastases (stage III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002109-22 Sponsor Protocol Number: 02/05/Hü Start Date*: 2005-12-01
    Sponsor Name:Medical University of Vienna
    Full Title: Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure
    Medical condition: both investigated drugs are well established in the treatment of heart failure or hypertension respectively. As the investigateed Patients have this conditions according to the inclusion criteria, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004467-31 Sponsor Protocol Number: DECENDO Start Date*: 2019-04-05
    Sponsor Name:
    Full Title: An exploratory study: Dendritic cells for immunotherapy of metastatic endometrial cancer patients
    Medical condition: metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004325-16 Sponsor Protocol Number: RC31/16/8407 Start Date*: 2016-12-22
    Sponsor Name:University Hospital of Toulouse
    Full Title: Long term evaluation of infants aged from 3 to 4 years old included in the OTBB2 study (repeated administrations of oxytocin in infants with PWS aged from 0 to 6 months) and comparison with not tre...
    Medical condition: Prader Willi Syndrom
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005230-37 Sponsor Protocol Number: HPV01/01 Start Date*: 2008-04-02
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV1...
    Medical condition: Adult female patients, with histological evidence of Vulvar intraepithelial neoplasia (VIN) grade III lesions of the squamous cell type, positive for HPV (Human Papilloma Virus)16.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2022-001374-60 Sponsor Protocol Number: MOB-02 Start Date*: 2022-07-21
    Sponsor Name:BCN Peptides
    Full Title: A randomized, double blinded, placebo controlled clinical trial to evaluate the antipruritic efficacy of the topical application of PARENTIDE cream in histamine-induced itch in healthy volunteers
    Medical condition: Treatment of pruritus or uticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001745-42 Sponsor Protocol Number: 3045 Start Date*: 2005-12-06
    Sponsor Name:University of Liverpool and Royal Liverpool University Hospital
    Full Title: BCR-ABL Peptide Vaccination in Normal Subjects.An investigation in normal subjects with HLA-A3 and HLA-B8, as an extension of an identical study in patients with Chronic Myeloid Leukaemia.
    Medical condition: Healthy Subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000398-64 Sponsor Protocol Number: VHIO18001 Start Date*: 2018-06-18
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Patterns of uptake of 18F-FDG and 68Ga-DOTA PET in advanced neuroendoctrine tumors
    Medical condition: Gastroenteropancreatic neuroendocrine tumor disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001434-34 Sponsor Protocol Number: MPN19H2 Start Date*: 2019-07-04
    Sponsor Name:Department of haematology, Zealand university hospital
    Full Title: Dual Vaccine Trial in Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10028576 Myeloproliferative disorder LLT
    20.1 100000004864 10036061 Polycythemia vera LLT
    20.1 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002411-26 Sponsor Protocol Number: UV1/hTERT-2012-P Start Date*: 2013-03-18
    Sponsor Name:Oslo University Hospital
    Full Title: A PHASE I/IIA STUDY OF UV1 VACCINATION IN PATIENTS WITH HORMONE-SENSITIVE METASTATIC PROSTATE CANCER.
    Medical condition: Patients with advanced oligometastatic prostate cancer (PCa) without lung and/or liver metastases who are eligible to Complete Androgen Blockade therapy (GnRH-agonist combined with anti-androgen).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004686-15 Sponsor Protocol Number: LUD 03-007 Start Date*: 2005-08-04
    Sponsor Name:Ludwig Institute For Cancer Research
    Full Title: Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma ...
    Medical condition: HLA-A2 patients with metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000765-12 Sponsor Protocol Number: MICORYX Start Date*: 2011-08-22
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer
    Medical condition: advanced MSI-H colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007734-19 Sponsor Protocol Number: P53SLP01/01 Start Date*: 2008-07-03
    Sponsor Name:University Medical Center Groningen, UMCG-Department of Gynaecologic Oncology
    Full Title: p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial.
    Medical condition: This is an uncontrolled, mono-centre, phase II single dose trial for patients with ovarian cancer, who have a rising serum tumor marker CA-125 after previous treatment (surgery and platinum based c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA